The Nutshell: FDA OKs siRNA Ebola Drug

FDA OKs siRNA Ebola Drug

The US Food and Drug Administration gives the green light to deploy an experimental short interfering RNA treatment against Ebola.

By Kerry Grens | September 23, 2014

WIKIMEDIA, RICHARD ROBINSON

Although TKM-Ebola, a short interfering RNA (siRNA) therapy to treat Ebola infection, has not been approved for use in humans, the US Food and Drug Administration (FDA) is allowing for “compassionate use” of the medication. In other words, even though a drug is not fully vetted, the dire circumstances of the patients justify risky measures. Tekmira Pharmaceutical, the drug’s manufacturer, announced in a press release yesterday (September 22) that the FDA and Health Canada will “allow the use of our investigational therapeutic in more patients.”

 

Already, Tekmira has provided the medication to several Ebola patients “and the repeat infusions have been well tolerated,” according to the statement. “However, it must be kept in mind that any uses of the product under expanded access, does not constitute controlled clinical trials.”

 

David Kroll at Forbes pointed out that the successful administration of TKM-Ebola in monkeys saved the animals from a strain of the virus that circulated in 1995. “On one hand, this shows that TKM-Ebola could be effective against a strain separated by almost 20 years, but is no guarantee that it will against the currently-circulating strain,” he wrote.

 

USA Today reported that one of the patients who has taken TKM-Ebola is Richard Sacra, a US physician who became infected in Liberia and is now being treated in Nebraska. Sacra also received a blood transfusion from another doctor who survived the infection after taking ZMapp, an experimental monoclonal antibody therapy. According to the news report, “While it’s too early to know if TKM-Ebola will work on more patients, [TKM-Ebola researcher Thomas] Geisbert said he’s encouraged [that] Sacra was able to take the drug safely. That’s no small feat, he said. Experimental drugs with unknown effects are usually tested in healthy people. Sacra was acutely ill when he received the drug.”

 

Forbes’s Kroll cautioned that given the limited supply of medication Tekmira has available to distribute, data from patients given compassionate use may not be sufficient to offer reliable insight into the effectiveness of the drug.

Tags

siRNA, RNAi, infectious disease, FDA, ebola, drug development and compassionate use

 

 

Latest News: How did the 'Berlin patient' rid himself of HIV?





Eric Risberg/AP Photo

 

Timothy Ray Brown, known by many researchers as "the Berlin patient," is the only person to have been cured of an HIV infection.

How did the 'Berlin patient' rid himself of HIV?

Researchers are closer to unraveling the mystery of how Timothy Ray Brown, the only human cured of HIV, defeated the virus, according to a new study. Although the work doesn’t provide a definitive answer, it rules out one possible explanation.

 

Brown remains one of the most studied cases in the HIV epidemic’s history. In 2006, after living with the virus for 11 years and controlling his infection with antiretroviral drugs (ARVs), he learned that he had developed acute myeloid leukemia. (The leukemia has no known relationship to HIV infection or treatment.) Chemotherapy failed, and the next year Brown, an American then living in Berlin, received the first of two bone marrow transplants—a common treatment for this cancer—and ditched his ARVs. When HIV-infected people stop taking ARVs, levels of HIV typically skyrocket within weeks. Yet researchers scouring Brown’s blood over the past 7 years have found only traces of the viral genetic material, none of which can replicate.
 
Today, researchers point to three different factors that could independently or in combination have rid Brown’s body of HIV. The first is the process of conditioning, in which doctors destroyed Brown’s own immune system with chemotherapy and whole body irradiation to prepare him for his bone marrow transplant. His oncologist, Gero Hütter, who was then with the Free University of Berlin, also took an extra step that he thought might not only cure the leukemia but also help rid Brown’s body of HIV. He found a bone marrow donor who had a rare mutation in a gene that cripples a key receptor on white blood cells the virus uses to establish an infection. (For years, researchers referred to Brown as “the Berlin patient.”) The third possibility is his new immune system attacked remnants of his old one that held HIV-infected cells, a process known as graft versus host disease.
 
In the new study, a team led by immunologist Guido Silvestri of Emory University in Atlanta, designed an unusual monkey experiment to test these possibilities.
 
Bone marrow transplants work because of stem cells. Modern techniques avoid actually aspirating bone marrow, and instead can sift through blood and pluck out the stem cells needed for a transplant to “engraft.” So the researchers first drew blood from three rhesus macaque monkeys, removed stem cells, and put the cells in storage. They then infected these animals and three control monkeys with a hybrid virus, known as SHIV, that contains parts of the simian and human AIDS viruses. All six animals soon began receiving ARVs (which respond better to SHIVs than SIV itself), and SHIV levels in the blood quickly dropped below the level of detection on standard tests, as expected.
 
A few months later, the three monkeys that had stored stem cells underwent whole body irradiation to condition their bodies and then had their own stem cells reinfused. After the cells engrafted, a process that took a few more months, the researchers stopped ARVs in the three animals and in the three controls. SHIV quickly came screaming back in the three controls and two of the transplanted animals. (One of the transplanted monkeys did not have the virus rebound but its kidneys failed and the researchers euthanized it.)
 
The team, which publishes its work online in PLOS Pathogens today, concludes that conditioning by itself likely cannot rid the body of the AIDS virus. Silvestri explains that the monkey study was a proof-of-principle experiment that cleanly isolated the effects of conditioning alone. “There’s no way to do this in humans,” he says.
 
 “It’s an important study and it’s a very useful model,” says Daniel Kuritzkes of Brigham & Women’s Hospital in Cambridge, Massachusetts, who wasn’t connected to the research.
Kuritzkes and colleagues are particularly interested in the experiment because two of their own HIV-infected patients with leukemia received bone marrow transplants from donors who did not have HIV-resistant cells. For several months after stopping ARVs, HIV remained at bay in both men, raising hopes that the resistant donor cells were not a factor. But the virus eventually returned in each patient. Kuritzkes suspects that the transplants did reduce the amount of HIV left in the patients’ bodies—known as the viral reservoir—but the virus resurfaced because it continued to copy itself and eventually overwhelmed the immune responses against it.
 
Although the study shows that conditioning by itself likely cannot eliminate an HIV infection, the study leaves open the possibility that graft versus host disease played a central role in Brown’s cure. Unlike Brown and Kuritzkes’s two patients, the transplanted monkeys received their own stem cells, which did not trigger a graft versus host response. “At the end of the day that might be an important component,” Silvestri says. He also thinks it might help reduce the reservoir size to treat monkeys with ARVs for longer than a few months.
 
Silvestri hopes to do future monkey experiments that test the different variables, including transplanting the animals with viral-resistant blood cells that mimic the ones that Brown received. “The best scientific studies raise as many questions as answers,” says Steven Deeks, a researcher and clinician at the University of California, San Francisco, who has treated and studied Brown. “Unfortunately, the heroic efforts that went into this study failed to provide a definitive answer regarding the riddles of the Berlin patient. The model will likely need to be further optimized, and at the very least, the macaques treated with antiretroviral therapy for longer periods of time. But I am confident the team will figure this out.”

By Jon Cohen               

25 September 2014 3:00 pm

 

     

Jon is a staff writer for Science.
Email Jon

 

Related content:

• Strategies against HIV/AIDS
• HIV resurfaces in 'Mississippi baby' many presumed cured
• Cure setbacks force HIV researchers to reset sights

Posted in Health